Universal Genetic Testing Versus Guidelines-Directed Testing for Germline Pathogenic Variants Among Non-Western Patients With Breast Cancer

NCT04920656 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-03-19

No results posted yet for this study

Summary

The study aims to examinethe pattern and frequency of pathogenic variants among all newly diagnosed breast cancer patients in a genetically distinct population. Additionally, the uptake rate of "cascade family screening" , frequency of pathogenic variants and barriers against testing will be studied.

Conditions

Sponsors & Collaborators

  • King Hussein Cancer Center

    lead OTHER

Principal Investigators

  • Hikmat Abdel-Razeq · King Hussein Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2025-02-01
Completion
2025-02-01

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920656 on ClinicalTrials.gov